blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2824183

EP2824183 - Methods for producing bispecific antibodies [Right-click to bookmark this link]
Former [2015/03]Antibody substituting for function of blood coagulation factor VIII
[2019/45]
StatusNo opposition filed within time limit
Status updated on  04.06.2021
Database last updated on 24.04.2024
FormerThe patent has been granted
Status updated on  26.06.2020
FormerGrant of patent is intended
Status updated on  22.03.2020
FormerExamination is in progress
Status updated on  28.02.2020
FormerGrant of patent is intended
Status updated on  16.10.2019
FormerExamination is in progress
Status updated on  16.12.2016
Most recent event   Tooltip02.06.2023Lapse of the patent in a contracting state
New state(s): HU		published on 05.07.2023  [2023/27]
Applicant(s)For all designated states
CHUGAI SEIYAKU KABUSHIKI KAISHA
5-1, Ukima 5-chome
Kita-ku
Tokyo, 115-8543 / JP
[2015/03]
Inventor(s)01 / Kojima, Tetsuo
c/o Chugai Seiyaku Kabushiki Kaisha
135, Komakado 1-chome, Gotenba-shi
Shizuoka 4128513 / JP
02 / Hattori, Kunihiro
c/o Chugai Seiyaku Kabushiki Kaisha
135, Komakado 1-chome, Gotenba-shi
Shizuoka 4128513 / JP
03 / Soeda, Tetsuhiro
c/o Chugai Seiyaku Kabushiki Kaisha
135, Komakado 1-chome, Gotenba-shi
Shizuoka 4128513 / JP
04 / Miyazaki, Taro
c/o Chugai Seiyaku Kabushiki Kaisha
135, Komakado 1-chome, Gotenba-shi
Shizuoka 4128513 / JP
05 / Saito, Hiroyuki
c/o Chugai Seiyaku Kabushiki Kaisha
135, Komakado 1-chome, Gotenba-shi
Shizuoka 4128513 / JP
 [2015/03]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[2020/31]
Former [2015/03]Vossius & Partner
Siebertstrasse 3
81675 München / DE
Application number, filing date14176527.131.03.2006
[2015/03]
Priority number, dateJP2005011251408.04.2005         Original published format: JP 2005112514
[2015/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2824183
Date:14.01.2015
Language:EN
[2015/03]
Type: B1 Patent specification 
No.:EP2824183
Date:29.07.2020
Language:EN
[2020/31]
Search report(s)(Supplementary) European search report - dispatched on:EP17.12.2014
ClassificationIPC:C07K16/00
[2019/45]
CPC:
C07K16/40 (EP,US); C07K16/36 (US); A61P43/00 (EP);
A61P7/00 (EP); A61P7/02 (EP); A61P7/04 (EP);
C07K16/00 (EP,US); C07K16/468 (US); C07K2317/24 (US);
C07K2317/31 (EP,US); C07K2317/56 (US); C07K2317/622 (US);
C07K2317/75 (US) (-)
Former IPC [2015/03]C12N15/09, A61K39/395, A61P7/04, C07K16/40, C07K16/46
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2015/35]
Former [2015/03]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Verfahren zur Herstellung bispezifischer Antikörper[2019/45]
English:Methods for producing bispecific antibodies[2019/45]
French:Procédé pour la production d'anticorps bispécifiques[2019/45]
Former [2015/03]Antikörperersatz für Blutgerinnungsfaktor VIII
Former [2015/03]Antibody substituting for function of blood coagulation factor VIII
Former [2015/03]Substitution des anticorps de la fonction du facteur VIII de coagulation sanguine
Examination procedure13.07.2015Amendment by applicant (claims and/or description)
13.07.2015Examination requested  [2015/35]
16.12.2016Despatch of a communication from the examining division (Time limit: M06)
21.06.2017Reply to a communication from the examining division
07.12.2017Despatch of a communication from the examining division (Time limit: M06)
06.06.2018Reply to a communication from the examining division
11.10.2018Despatch of a communication from the examining division (Time limit: M04)
21.02.2019Reply to a communication from the examining division
17.10.2019Communication of intention to grant the patent
24.02.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
24.02.2020Fee for grant paid
24.02.2020Fee for publishing/printing paid
23.03.2020Communication of intention to grant the patent
16.06.2020Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP06730769.4  / EP1876236
Opposition(s)30.04.2021No opposition filed within time limit [2021/27]
Fees paidRenewal fee
06.11.2014Renewal fee patent year 03
06.11.2014Renewal fee patent year 04
06.11.2014Renewal fee patent year 05
06.11.2014Renewal fee patent year 06
06.11.2014Renewal fee patent year 07
06.11.2014Renewal fee patent year 08
06.11.2014Renewal fee patent year 09
24.03.2015Renewal fee patent year 10
25.03.2016Renewal fee patent year 11
23.03.2017Renewal fee patent year 12
21.03.2018Renewal fee patent year 13
21.03.2019Renewal fee patent year 14
23.03.2020Renewal fee patent year 15
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU31.03.2006
AT29.07.2020
CY29.07.2020
CZ29.07.2020
EE29.07.2020
ES29.07.2020
FI29.07.2020
IT29.07.2020
LT29.07.2020
LV29.07.2020
MC29.07.2020
NL29.07.2020
PL29.07.2020
RO29.07.2020
SE29.07.2020
SI29.07.2020
SK29.07.2020
BG29.10.2020
GR30.10.2020
IS29.11.2020
PT30.11.2020
BE31.03.2021
IE31.03.2021
LU31.03.2021
[2023/27]
Former [2023/24]AT29.07.2020
CY29.07.2020
CZ29.07.2020
EE29.07.2020
ES29.07.2020
FI29.07.2020
IT29.07.2020
LT29.07.2020
LV29.07.2020
MC29.07.2020
NL29.07.2020
PL29.07.2020
RO29.07.2020
SE29.07.2020
SI29.07.2020
SK29.07.2020
BG29.10.2020
GR30.10.2020
IS29.11.2020
PT30.11.2020
BE31.03.2021
IE31.03.2021
LU31.03.2021
Former [2022/34]AT29.07.2020
CZ29.07.2020
EE29.07.2020
ES29.07.2020
FI29.07.2020
IT29.07.2020
LT29.07.2020
LV29.07.2020
MC29.07.2020
NL29.07.2020
PL29.07.2020
RO29.07.2020
SE29.07.2020
SI29.07.2020
SK29.07.2020
BG29.10.2020
GR30.10.2020
IS29.11.2020
PT30.11.2020
BE31.03.2021
IE31.03.2021
LU31.03.2021
Former [2022/09]AT29.07.2020
CZ29.07.2020
EE29.07.2020
ES29.07.2020
FI29.07.2020
IT29.07.2020
LT29.07.2020
LV29.07.2020
MC29.07.2020
NL29.07.2020
PL29.07.2020
RO29.07.2020
SE29.07.2020
SI29.07.2020
SK29.07.2020
BG29.10.2020
GR30.10.2020
IS29.11.2020
PT30.11.2020
IE31.03.2021
LU31.03.2021
Former [2022/07]AT29.07.2020
CZ29.07.2020
EE29.07.2020
ES29.07.2020
FI29.07.2020
IT29.07.2020
LT29.07.2020
LV29.07.2020
MC29.07.2020
NL29.07.2020
PL29.07.2020
RO29.07.2020
SE29.07.2020
SI29.07.2020
SK29.07.2020
BG29.10.2020
GR30.10.2020
IS29.11.2020
PT30.11.2020
IE31.03.2021
Former [2021/45]AT29.07.2020
CZ29.07.2020
EE29.07.2020
ES29.07.2020
FI29.07.2020
IT29.07.2020
LT29.07.2020
LV29.07.2020
MC29.07.2020
NL29.07.2020
PL29.07.2020
RO29.07.2020
SE29.07.2020
SI29.07.2020
SK29.07.2020
BG29.10.2020
GR30.10.2020
IS29.11.2020
PT30.11.2020
Former [2021/36]AT29.07.2020
CZ29.07.2020
EE29.07.2020
ES29.07.2020
FI29.07.2020
IT29.07.2020
LT29.07.2020
LV29.07.2020
NL29.07.2020
PL29.07.2020
RO29.07.2020
SE29.07.2020
SI29.07.2020
SK29.07.2020
BG29.10.2020
GR30.10.2020
IS29.11.2020
PT30.11.2020
Former [2021/28]AT29.07.2020
CZ29.07.2020
EE29.07.2020
ES29.07.2020
FI29.07.2020
IT29.07.2020
LT29.07.2020
LV29.07.2020
NL29.07.2020
PL29.07.2020
RO29.07.2020
SE29.07.2020
SK29.07.2020
BG29.10.2020
GR30.10.2020
IS29.11.2020
PT30.11.2020
Former [2021/22]AT29.07.2020
CZ29.07.2020
EE29.07.2020
ES29.07.2020
FI29.07.2020
IT29.07.2020
LT29.07.2020
LV29.07.2020
NL29.07.2020
PL29.07.2020
RO29.07.2020
SE29.07.2020
BG29.10.2020
GR30.10.2020
IS29.11.2020
PT30.11.2020
Former [2021/20]AT29.07.2020
ES29.07.2020
FI29.07.2020
IT29.07.2020
LT29.07.2020
LV29.07.2020
NL29.07.2020
PL29.07.2020
SE29.07.2020
BG29.10.2020
GR30.10.2020
IS29.11.2020
PT30.11.2020
Former [2021/17]AT29.07.2020
ES29.07.2020
FI29.07.2020
LT29.07.2020
LV29.07.2020
NL29.07.2020
PL29.07.2020
SE29.07.2020
BG29.10.2020
GR30.10.2020
IS29.11.2020
PT30.11.2020
Former [2021/10]AT29.07.2020
ES29.07.2020
FI29.07.2020
LT29.07.2020
LV29.07.2020
PL29.07.2020
SE29.07.2020
BG29.10.2020
GR30.10.2020
IS29.11.2020
PT30.11.2020
Former [2021/09]AT29.07.2020
ES29.07.2020
FI29.07.2020
LT29.07.2020
SE29.07.2020
BG29.10.2020
GR30.10.2020
PT30.11.2020
Former [2021/08]ES29.07.2020
FI29.07.2020
LT29.07.2020
SE29.07.2020
BG29.10.2020
PT30.11.2020
Former [2021/07]FI29.07.2020
LT29.07.2020
Documents cited:Search[A]WO9607754  (SCRIPPS RESEARCH INST [US]) [A] 1-9 * abstract * * pages 1-5 * * pages 54-60 *;
 [XI]WO9850431  (GENENTECH INC [US]) [X] 3,6,9 * abstract * [I] 1,2,4,5,7,8;
 [XI]US2002062010  (ARATHOON W ROBERT [US], et al) [X] 3,6,9 * abstract * * paragraphs [0002] , [0028]; figure 1C; example 4; claims 1-27 * [I] 1,2,4,5,7,8;
 [XI]WO2004009618  (CRUCELL HOLLAND BV [NL], et al) [X] 3,6,9 * abstract * * page 21; figures 5, 6; examples 1, 2, 4, 7, 9; claims 1-54 * [I] 1,2,4,5,7,8;
 [XI]WO2004065611  (CHUGAI PHARMACEUTICAL CO LTD [JP], et al) [X] 3,6,9 * abstract * [I] 1,2,4,5,7,8;
 [XI]WO2004111233  (CHUGAI PHARMACEUTICAL CO LTD [JP], et al) [X] 3,6,9 * abstract * [I] 1,2,4,5,7,8;
 [XPI]EP1605058  (CHUGAI PHARMACEUTICAL CO LTD [JP]) [XP] 3,6,9 * abstract * * paragraphs [0009] - [0012] - [0 24] - [0025] - [0 30] , [0 37] - [0042]; figure 2; claims 1-10 * [I] 1,2,4,5,7,8;
 [XI]  - MERCHANT A MARGARET ET AL, "An efficient route to human bispecific IgG", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, (19980701), vol. 16, no. 7, doi:10.1038/NBT0798-677, ISSN 1087-0156, pages 677 - 681, XP002141015 [X] 3,6,9 * the whole document * * in particular abstract, Figure 1, page 679-680* [I] 1,2,4,5,7,8

DOI:   http://dx.doi.org/10.1038/nbt0798-677
 [XI]  - CARTER PAUL, "Bispecific human IgG by design", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, (20010101), vol. 248, no. 1-2, doi:10.1016/S0022-1759(00)00339-2, ISSN 0022-1759, pages 7 - 15, XP002974199 [X] 3,6,9 * the whole document * * in particular abstract, page 10 * [I] 1,2,4,5,7,8

DOI:   http://dx.doi.org/10.1016/S0022-1759(00)00339-2
 [A]  - FIGINI M ET AL, "In Vitro Assembly of Repertoires of Antibody Chains on the Surface of Phage by Renaturation", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 239, no. 1, doi:10.1006/JMBI.1994.1351, ISSN 0022-2836, (19940526), pages 68 - 78, (19940526), XP024009507 [A] 1-9 * the whole document *

DOI:   http://dx.doi.org/10.1006/jmbi.1994.1351
 [A]  - VAUGHAN T J ET AL, "HUMAN ANTIBODIES WITH SUB-NANOMOLAR AFFINITIES ISOLATED FROM A LARGE NON-IMMUNIZED PHAGE DISPLAY LIBRARY", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, (19960301), vol. 14, doi:10.1038/NBT0396-309, ISSN 1087-0156, pages 309 - 314, XP000196144 [A] 1-9 * the whole document *

DOI:   http://dx.doi.org/10.1038/nbt0396-309
ExaminationWO2004097041
    - JIRHOLT P ET AL, "Exploiting sequence space: shuffling in vivo formed complementarity determining regions into a master framework", GENE, ELSEVIER, AMSTERDAM, NL, (19980701), vol. 215, no. 2, doi:10.1016/S0378-1119(98)00317-5, ISSN 0378-1119, pages 471 - 476, XP004149272

DOI:   http://dx.doi.org/10.1016/S0378-1119(98)00317-5
by applicantUS3773919
 EP0058481
 EP0133988
 EP0239400
 US4945050
 EP0404097
 WO9203918
 WO9311161
 WO9312227
 WO9317706
 WO9402602
 WO9425585
 WO9602576
 WO9634096
 WO9633735
 WO9951743
    - MERTENS K ET AL., THROMB. HAEMOST., (1999), vol. 82, pages 209 - 217
    - LAPAN KA ET AL., THROMB. HAEMOST., (1998), vol. 80, pages 418 - 422
    - SEGAL DM ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, (2001), vol. 248, pages 1 - 6
    - HOLLIGER, P. ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448
    - PLUCKTHUN, The Pharmacology of Monoclonal Antibodies, SPRINGER VERLAG, (1994), vol. 113, pages 269 - 315
    - MILSTEIN C ET AL., NATURE, (1983), vol. 305, pages 537 - 540
    - RIDGWAY JB ET AL., PROTEIN ENGINEERING, (1996), vol. 9, pages 617 - 621
    - MERCHANT AM ET AL., NATURE BIOTECHNOLOGY, (1998), vol. 16, pages 677 - 681
    - KELER T ET AL., CANCER RESEARCH, (1997), vol. 57, pages 4008 - 4014
    - BRENNAN M ET AL., SCIENCE, (1985), vol. 229, pages 81 - 83
    - KOSTELNY SA ET AL., J. OF IMMUNOLOGY, (1992), vol. 148, pages 1547 - 53
    - HOLLIGER P ET AL., PROC NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448
    - KIPRIYANOV SM ET AL., J. OF MOLECULAR BIOLOGY, (1999), vol. 293, pages 41 - 56
    - ZHU Z ET AL., PROTEIN SCIENCE, (1997), vol. 6, pages 781 - 788
    - MALLENDER WD ET AL., J. OF BIOLOGICAL CHEMISTRY, (1994), vol. 269, pages 199 - 206
    - SATO K ET AL., CANCER RESEARCH, (1993), vol. 53, pages 851 - 856
    - "An efficient route to human bispecific IgG", NATURE BIOTECHNOLOGY, (1998), vol. 16, pages 677 - 681
    - NILSSON 1M ET AL., J. INTERN. MED., (1992), vol. 235, pages 25 - 32
    - L6FQVIST T ET AL., J. INTERN. MED., (1997), vol. 241, pages 395 - 400
    - LANGER ET AL., J. BIOMED. MATER. RES., (1981), vol. 15, pages 267 - 277
    - LANGER, CHEMTECH, (1982), vol. 12, pages 98 - 105
    - SIDMAN ET AL., BIOPOLYMERS, (1983), vol. 22, pages 547 - 556
    - KREBBER ET AL., J. IMMUNOL. METHODS, (1997), vol. 201, pages 35 - 55
    - J. IMMUNOL. METHODS, (1997), vol. 201, pages 35 - 55
    - KREBBER ET AL., J. MIMUNOL. METHODS, (1997), vol. 201, pages 35 - 55
    - RIDGWAY ET AL., PROTEIN ENG., (1996), vol. 9, pages 617 - 621
    - PROC. NATL. ACAD. SCI. USA., (1984), vol. 81, page 1075
    - EMBO. J., (1987), vol. 6, page 2939
    - LEYTUS ET AL., BIOCHEMISTRY, (1986), vol. 25, page 5098
    - MARIETTE ET AL., ARTHRITIS RHEUM, (1993), vol. 36, pages 1315 - 1324
    - MARK ET AL., J MOL BIOL., (1991), vol. 222, pages 581 - 597
    - DEMAISON ET AL., IMMUNOGENETICS, (1995), vol. 42, pages 342 - 352
    - PROTEIN ENGINEERING, (1996), vol. 9, pages 617 - 621
    - KIPPS ET AL., J. CLIN. INVEST., (1991), vol. 87, pages 2087 - 2096
    - WELSCHOF ET AL., J. IMMUNOL. METHOD., (1995), vol. 179, pages 203 - 214
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.